公开(公告)号：US20220002692A1

公开(公告)日：2022-01-06

申请号：US17296597

申请日：2019-11-26

Applicant: JOINT STOCK COMPANY "BIOCAD"

Inventor： Konstantin Viktorovich SEVERINOV ,  Sergey Anatolevich SHMAKOV ,  Daria Nikolaevna ARTAMONOVA ,  Ignatiy Igorevich GORYANIN ,  Olga Sergeevna MUSHAROVA ,  Iuliia Valerevna PISKUNOVA ,  Iana Vitalevna FEDOROVA ,  Tatyana Igorevna ZYUBKO ,  Mikhail Alekseevich KHODORKOVSKIY ,  Georgii Evgenevich POBEGALOV ,  Anatolii Nikolaevich ARSENIEV ,  Polina Anatolevna SELKOVA ,  Aleksandra Andreevna VASILEVA ,  Tatiana Olegovna ARTAMONOVA ,  Marina Viktorovna ABRAMOVA

IPC: C12N9/22 ,  C12N15/90 ,  C12N15/11

Abstract: The present invention describes a novel bacterial nuclease of the CRISPR-Cas9 system from the bacterium Clostridium celluloliticum, as well as the use thereof to form strictly specific double-strand breaks in a DNA molecule. This nuclease has unusual properties and may be used as a tool for introducing modifications at strictly defined sites in the genomic DNA sequence of unicellular or multicellular organisms. Thus, the versatility of the available CRISPR-Cas9 systems is increased, which will enable the use of Cas9 nucleases from various organisms for cutting genomic or plasmid DNA in a larger number of specific sites and in wider temperature ranges. Further, provided is more facile editing of the genome of the biotechnologically significant bacterium Clostridium celluloliticum.

公开(公告)号：US20210246138A1

公开(公告)日：2021-08-12

申请号：US17264670

申请日：2019-07-31

Applicant: JOINT STOCK COMPANY "BIOCAD"

Inventor： Aleksei Leonidovich MINDICH ,  Anna Jur'evna CHESTNOVA ,  Mariia Andreevna KASATKINA ,  Andrei Ivanovich ALAFINOV ,  Aleksei Sergeevich GAVRILOV ,  Anton Aleksandrovich EVDOKIMOV ,  Liliana Vyacheslavovna LENSHMIDT ,  Elena Aleksandrovna MAKSIMENKO ,  Mariia Sergeevna MISHINA ,  Sergei Aleksandrovich SILONOV ,  Evgenii Jur'evich SMIRNOV ,  Pavel Andreevich IAKOVLEV ,  Dmitry Valentinovich MOROZOV

IPC: C07D471/04 ,  A61P35/00

Abstract: The present invention relates to novel compounds of formula I: which have the properties of CDK8/19 inhibitors, to a pharmaceutical composition comprising said compounds, and to use thereof as a medicine for treating diseases and disorders.

公开(公告)号：US20200369771A1

公开(公告)日：2020-11-26

申请号：US16605865

申请日：2018-04-11

Applicant: JOINT STOCK COMPANY "BIOCAD"

Inventor： Andrey Borisovich ULITIN ,  Victoria Mikhailovna EKIMOVA ,  Ekaterina Vladimirovna SOFRONOVA, ,  Yulia Sergeevna CHERNYKH ,  Sergei Andreevich AGEEV ,  Anna Konstantinovna VLADIMIROVA ,  Aleksei Aleksandrovich ALEKSANDROV ,  Pavel Alekseevich GREBNEV ,  Valery Vladimirovich SOLOVYEV ,  Iakov Iurevich USTIUGOV ,  Pavel Andreevich IAKOVLEV ,  Timofey Aleksandrovich NEMANKIN ,  Dmitry Valentinovich MOROZOV

IPC: C07K16/28 ,  A61K45/06 ,  A61K39/395

Abstract: The present invention relates to the field of biotechnology and provides antibodies that specifically binds to PD-L1. The invention also relates to DNA encoding said antibodies, to corresponding expression vectors and to methods of producing, and to methods of treatment using said antibodies.

公开(公告)号：US20200270345A1

公开(公告)日：2020-08-27

申请号：US16753587

申请日：2018-10-03

Applicant: JOINT STOCK COMPANY "BIOCAD"

Inventor： Kirill Vladimirovich SOLOVYEV ,  Andrei Borisovich ULITIN ,  Timofey Aleksandrovich NEMANKIN ,  Valery Vladimirovich SOLOVYEV ,  Dmitry Valentinovich MOROZOV

IPC: C07K16/28

Abstract: The present invention relates to the field of bioengineering, specifically to antibodies or their antigen-binding fragments, and to the use thereof. More particularly, the present invention relates to antibodies that bind specifically to CD47 and PD-L1. The invention also relates to a nucleic acid that codes for the given antibody or for the antigen-binding fragment thereof, to an expression vector, to a method of producing the antibody, and to a use of the aforementioned antibodies and compositions in cancer treatment.

公开(公告)号：US20190352276A1

公开(公告)日：2019-11-21

申请号：US16461537

申请日：2017-11-16

Applicant: Joint Stock Company "Biocad"

Inventor： Aleksey Sergeevich Gavrilov ,  Pavel Aleksandrovich Aleshunin ,  Svetlana Leonidovna Gorbunova ,  Mikhail Vladimirovich Rekharsky ,  Natalia Vladimirovna Kozhemyakina ,  Anna Aleksandrovna Kukushkina ,  Anna Sergeevna Kushakova ,  Leonid Evgen`evich Mikhaylov ,  Alexander Moldavsky ,  Aleksandra Vladimirovna Popkova ,  Sergey Aleksandrovich Silonov ,  Svetlana Sergeevna Smirnova ,  Pavel Andreevich Iakovlev

IPC: C07D401/04 ,  C07D401/14 ,  C07D403/04 ,  C07D403/12 ,  C07D471/04

Abstract: The present invention relates to a new compound of formula I: or pharmaceutically acceptable salt, solvate or stereoisomer thereof, wherein: V1 is C or N, V2 is C(R2) or N, whereby if V1 is C then V2 is N, if V1 is C then V2 is C(R2), or if V1 is N then V2 is C(R2); each n, k is independently 0, 1; each R2, R11 is independently H, D, Hal, CN, NR′R″, C(O)NR′R″, C1-C6 alkoxy; R3 is H, D, hydroxy, C(O)C1-C6 alkyl, C(O)C2-C6 alkenyl, C(O)C2-C6 alkynyl, C1-C6 alkyl; R4 is H, Hal, CN, CONR′R″, hydroxy, C1-C6 alkyl, C1-C6 alkoxy; L is CH2, NH, O or chemical bond; R1 is selected from the group of the fragments, comprising: Fragment 1, Fragment 2, Fragment 3 each A1, A2, A3, A4 is independently CH, N, CHal; each A5, A6, A7, A8, A9 is independently C, CH or N; R5 is H, CN, Hal, CONR′R″, C1-C6 alkyl, non-substituted or substituted by one or more halogens; each R′ and R″ is independently selected from the group, comprising H, C1-C6 alkyl, C1-C6 cycloalkyl, aryl; R6 is selected from the group: [formula II] each R7, R8, R9, R10 is independently vinyl, methylacetylenyl; Hal is CI, Br, I, F, which have properties of inhibitor of Bruton's tyrosine kinase (Btk), to pharmaceutical compositions containing such compounds, and their use as pharmaceuticals for treatment of diseases and disorder.

公开(公告)号：US20170066843A1

公开(公告)日：2017-03-09

申请号：US15254225

申请日：2016-09-01

Applicant: CLOSED JOINT STOCK COMPANY "BIOCAD"

Inventor： Andrey Borisovich ULITIN ,  Stanislav Rudolfovich EVDOKIMOV ,  Valeriy Vladimirovich SOLOVIEV ,  Yulia Sergeevna CHERNYH ,  Olga Vladimirovna GONCHAROVA ,  Dmitriy Valerievich KORZHAVIN ,  Tatyana Veniaminovna CHERNOVSKAYA ,  Timofey Aleksandrovich NEMANKIN ,  Roman Alexeevich IVANOV ,  Dmitriy Valentinovich MOROZOV ,  Victoria Mikhailovna EKIMOVA ,  Ekaterina Vladimirovna SOFRONOVA ,  Yakov Yurevich USTYUGOV

IPC: C07K16/46 ,  A61K45/06 ,  C07K16/24 ,  A61K39/395

Abstract: The monoclonal IgG-type antibodies were suggested comprising variable domains represented by a combination of VHH-derivative with a variable domain of the light chain VL. Said antibodies can comprise amino acid substitutions at positions 44 and 45 (Kabat numbering) or combinations thereof. Antibodies of the invention possess increased affinity and improved aggregation stability.

Abstract translation: 提出了单克隆IgG型抗体，其包含由VHH衍生物与轻链VL的可变结构域组合表示的可变结构域。 所述抗体可以包含位置44和45（Kabat编号）或其组合的氨基酸取代。 本发明的抗体具有增加的亲和力和改进的聚集稳定性。

公开(公告)号：US12227572B2

公开(公告)日：2025-02-18

申请号：US17417686

申请日：2020-02-20

Applicant: JOINT STOCK COMPANY “BIOCAD”

Inventor： Olga Vladimirovna Britanova ,  Dmitry Borisovich Staroverov ,  Anna Valentinovna Evstrateva ,  Alexey Konstantinovich Misorin ,  Timofey Aleksandrovich Nemankin ,  Mariia Aleksandrovna Shchemeleva ,  Anna Konstantinovna Vladimirova ,  Arina Vitalevna Anikina ,  Roman Alekseevich Ivanov ,  Dmitry Valentinovich Morozov ,  Pavel Andreevich Iakovlev ,  Sergey Anatolievich Lukyanov

IPC: C07K16/28 ,  A61K39/00

Abstract: The invention relates to a monoclonal humanized antibody or antigen-binding fragment thereof that specifically bind to the TRBV9 family of the human T cell receptor. The invention also relates to a nucleic acid encoding said antibody or antigen-binding fragment thereof, an expression vector, a method for preparing said antibody, and use of said antibody in treatment of diseases or disorders associated with the human T cell receptor family. The invention is directed to generation of antibodies that can be used for treating, in particular AS, celiac disease and malignant blood diseases, the pathogenesis of which involves the TRBV9 family TCRs.

公开(公告)号：US12173075B2

公开(公告)日：2024-12-24

申请号：US16753488

申请日：2018-10-02

Applicant: JOINT STOCK COMPANY “BIOCAD”

Inventor： Ekaterina Vladimirovna Sofronova ,  Aleksei Konstantinovich Misorin ,  Aleksandr Nikolaevich Doronin ,  Timofey Aleksandrovich Nemankin ,  Aleksandra Aleksandrovna Sozonova ,  Galina Stepanovna Zhirivskaia ,  Sergey Aleksandrovich Legotsky ,  Anna Konstantinovna Vladimirova ,  Alina Valerevna Beliasnikova ,  Mariia Aleksandrovna Shchemeleva ,  Pavel Andreevich Iakovlev ,  Valery Vladimirovich Solovyev ,  Elena Andreevna Krendeleva ,  Natalia Evgenevna Pestova ,  Dmitry Valentinovich Morozov

IPC: C12N15/64 ,  C07K16/28 ,  A61K39/00 ,  A61K45/06

Abstract: The present disclosure relates to biotechnology and provides antibodies that specifically bind to IL-5Rα. The disclosure also relates to DNA encoding the antibodies, the corresponding expression vectors and methods of production thereof, as well as methods of treatment using the antibodies.

公开(公告)号：US20240091383A1

公开(公告)日：2024-03-21

申请号：US18274496

申请日：2022-01-28

Applicant: JOINT STOCK COMPANY «BIOCAD»

Inventor： Dmitriy Aleksandrovich MADERA ,  Anna Sergeevna VESELOVA ,  Aleksei Sergeevich SIUTKIN ,  Pavel Mikhailovich GERSHOVICH ,  Dmitry Valentinovich MOROZOV

IPC: A61K48/00 ,  C12N15/86

CPC classification number: A61K48/0058 ,  C12N15/86 ,  C12N2310/141 ,  C12N2310/31 ,  C12N2750/14143

Abstract: The present application relates to the fields of biotechnology, virology, genetics, and molecular biology. More specifically, the present invention relates to an isolated nucleic acid for producing a gene therapy viral product, said isolated nucleic acid comprising a nucleic acid that encodes the SMN1 protein having the amino acid sequence of SEQ ID NO: 1, and a nucleic acid that encodes the microRNA miR-23a, an expression cassette and a vector based thereon, as well as an AAV9-based recombinant virus for expressing the SMN1 gene in target cells, a pharmaceutical composition that includes said recombinant virus, and various uses of the above recombinant virus and the above composition.

公开(公告)号：US20230203171A1

公开(公告)日：2023-06-29

申请号：US17998567

申请日：2021-06-07

Applicant: JOINT STOCK COMPANY "BIOCAD"

Inventor： Dmitrii Aleksandrovich TOLSTYKH ,  Alina Aleksandrovna TSUKUR ,  Ekaterina Aleksandrovna LOMKOVA ,  Aleksandr Olegovich IAKOVLEV ,  Anton Aleksandrovich LUTCKII ,  Iuliia Nikolaevna LINKOVA ,  Arina Valerevna ZINKINA-ORIKHAN ,  Dmitry Valentinovich MOROZOV

IPC: C07K16/28 ,  A61K47/12 ,  A61K47/10 ,  A61K47/18 ,  A61K31/519 ,  A61K9/08 ,  A61P19/02 ,  A61P37/06

CPC classification number: C07K16/2866 ,  A61K47/12 ,  A61K47/10 ,  A61K47/183 ,  A61K31/519 ,  A61K9/08 ,  A61P19/02 ,  A61P37/06 ,  C07K2317/21

Abstract: The disclosure relates to the field of pharmacy and medicine, specifically to aqueous compositions of anti-IL-6R antibody levilimab which may be used as a medicinal product for treating IL-6R-associated diseases.